Search

Your search keyword '"Ghosh, Nilanjan"' showing total 315 results
Start Over Author "Ghosh, Nilanjan" Publication Year Range Last 3 years
315 results on '"Ghosh, Nilanjan"'

5. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

Author

Bond, David A, Switchenko, Jeffrey M, Villa, Diego, Maddocks, Kami, Churnetski, Michael C, Gerrie, Alina S, Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James Nathan, Barta, Stefan K, Hill, Brian T, Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max J, Danilov, Alexey V, Grover, Natalie Sophia, Mathews, Stephanie P, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I, Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S, Malecek, Mary-Kate, Kahl, Brad S, Flowers, Christopher R, Blum, Kristie, and Cohen, Jonathon B

Subjects
Rare Diseases, Prevention, Hematology, Lymphoma, Cancer, Adult, Humans, Lymphoma, Mantle-Cell, Prognosis, Prospective Studies, Recurrence, Treatment Outcome
Abstract

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Published
2021

15. Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).

Author

Assouline, Sarit, primary, Budde, Lihua Elizabeth, additional, Chavez, Julio C., additional, Diefenbach, Catherine S., additional, Dorritie, Kathleen Anne, additional, Ghosh, Nilanjan, additional, Olszewski, Adam J, additional, Lossos, Izidore S., additional, Mehta, Amitkumar, additional, Modi, Dipenkumar, additional, Naik, Seema, additional, Smith, Stephen Douglas, additional, Makadia, Sneha, additional, Pham, Song, additional, Wu, Hao, additional, Batlevi, Connie Lee, additional, To, Iris, additional, Wei, Michael C., additional, and Kamdar, Manali, additional

Published
2024
Full Text
View/download PDF

17. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

20. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

Author

Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Szafer-Glusman, Edith, Eckert, Karl, Neuenburg, Jutta K., and Goy, Andre

Published
2023
Full Text
View/download PDF

24. Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final Analysis of the Phase 2 PILOT Study

Author

Hoda, Daanish, primary, Sehgal, Alison, additional, Riedell, Peter A., additional, Ghosh, Nilanjan, additional, Hamadani, Mehdi, additional, Hildebrandt, Gerhard C, additional, Godwin, John E., additional, Reagan, Patrick M., additional, Wagner-Johnston, Nina, additional, Essell, James, additional, Nath, Rajneesh, additional, Solomon, Scott R., additional, Champion, Rebecca, additional, Licitra, Edward, additional, Fanning, Suzanne, additional, Gupta, Neel K., additional, Chow, Victor A., additional, Yuan, Brenda, additional, Yang, Zhi, additional, Ogasawara, Ken, additional, Thorpe, Jerill, additional, and Gordon, Leo I., additional

Published
2024
Full Text
View/download PDF

25. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Author

Palomba, M. Lia, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V, additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Singh, Ashvin, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, and Wang, Michael, additional

Published
2024
Full Text
View/download PDF

26. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

27. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Author

Sehgal, Alison, Hoda, Daanish, Riedell, Peter A, Ghosh, Nilanjan, Hamadani, Mehdi, Hildebrandt, Gerhard C, Godwin, John E, Reagan, Patrick M, Wagner-Johnston, Nina, Essell, James, Nath, Rajneesh, Solomon, Scott R, Champion, Rebecca, Licitra, Edward, Fanning, Suzanne, Gupta, Neel, Dubowy, Ronald, D'Andrea, Aleco, Wang, Lei, Ogasawara, Ken, Thorpe, Jerill, and Gordon, Leo I

Published
2022
Full Text
View/download PDF

29. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

30. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

Author

Shadman, Mazyar, Ahn, Kwang W., Kaur, Manmeet, Lekakis, Lazaros, Beitinjaneh, Amer, Iqbal, Madiha, Ahmed, Nausheen, Hill, Brian, Hossain, Nasheed M., Riedell, Peter, Gopal, Ajay K., Grover, Natalie, Frigault, Matthew, Brammer, Jonathan, Ghosh, Nilanjan, Merryman, Reid, Lazaryan, Aleksandr, Ram, Ron, Hertzberg, Mark, and Savani, Bipin

Subjects
AUTOGRAFTS, DIFFUSE large B-cell lymphomas, HEMATOPOIETIC stem cell transplantation, OVERALL survival, PROGRESSION-free survival
Abstract

In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24.7 months for the CAR-T cohort. Patients ages 18 and 75 with a diagnosis of DLBCL were included if they received auto-HCT (n = 281) or commercial CAR-T (n = 79) while in a CR. Patients undergoing auto-HCT with only one prior therapy line and CAR-T patients with a previous history of auto-HCT treatment were excluded. Endpoints included Progression-free survival (PFS), relapse rate, non-relapse mortality (NRM) and overall survival (OS). In univariate analysis, treatment with auto-HCT was associated with a higher rate of 2-year PFS (66.2% vs. 47.8%; p < 0.001), a lower 2-year cumulative incidence of relapse (27.8% vs. 48% ; p < 0.001), and a superior 2-year OS (78.9% vs. 65.6%; p = 0.037). In patients with early (within 12 months) treatment failure, auto-HCT was associated with a superior 2-year PFS (70.9% vs. 48.3% ; p < 0.001), lower 2-year cumulative incidence of relapse (22.8% vs. 45.9% ; p < 0.001) and trend for higher 2-year OS (82.4% vs. 66.1% ; p = 0.076). In the multivariable analysis, treatment with auto-HCT was associated with a superior PFS (hazard ratio 1.83; p = 0.0011) and lower incidence of relapse (hazard ratio 2.18; p < 0.0001) compared to CAR-T. In patients with relapsed LBCL who achieve a CR, treatment with auto-HCT is associated with improved clinical outcomes compared to CAR-T. These data support the consideration of auto-HCT in select patients with LBCL achieving a CR in the relapsed setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.

Author

Yifan Pang and Ghosh, Nilanjan

Subjects
CELL surface antigens, T-cell lymphoma, CD19 antigen, CHRONIC lymphocytic leukemia, CHIMERIC antigen receptors, CHRONIC leukemia
Abstract

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting the application of therapy in indolent diseases such as chronic lymphocytic leukemia (CLL). Alternative CAR targets and multispecific CAR are potential solutions to improving cellular therapy outcomes in BNHL. For Hodgkin lymphoma and T-cell lymphoma, several cell surface antigens have been studied as CAR targets, some of which already showed promising results in clinical trials. Some antigens are expressed by different lymphomas and could be used for designing tumor-agnostic CAR. Here, we reviewed the antigens that have been studied for novel CAR-based therapies, as well as CARs designed to target two or more antigens in the treatment of lymphoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

34. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Author

Dickinson, Michael, Briones, Javier, Herrera, Alex F., González-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C., Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, and Hutchings, Martin

Published
2021
Full Text
View/download PDF

35. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia

Author

Carraway, Hetty E., Sawalha, Yazeed, Gojo, Ivana, Lee, Min-Jung, Lee, Sunmin, Tomita, Yusuke, Yuno, Akira, Greer, Jackie, Smith, B. Douglas, Pratz, Keith W., Levis, Mark J., Gore, Steven D., Ghosh, Nilanjan, Dezern, Amy, Blackford, Amanda L., Baer, Maria R., Gore, Lia, Piekarz, Richard, Trepel, Jane B., and Karp, Judith E.

Published
2021
Full Text
View/download PDF

37. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

39. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

Author

Wang, Michael, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V., additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Dehner, Christine, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, Eliason, Laurie, additional, and Palomba, M. Lia, additional

Published
2023
Full Text
View/download PDF

40. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

Author

Budde, Lihua E., primary, Olszewski, Adam J., additional, Assouline, Sarit, additional, Lossos, Izidore S., additional, Diefenbach, Catherine, additional, Kamdar, Manali, additional, Ghosh, Nilanjan, additional, Modi, Dipenkumar, additional, Sabry, Waleed, additional, Naik, Seema, additional, Mehta, Amitkumar, additional, Nakhoda, Shazia K., additional, Smith, Stephen D., additional, Dorritie, Kathleen, additional, Jia, Ting, additional, Pham, Song, additional, Huw, Ling-Yuh, additional, Jing, Jing, additional, Wu, Hao, additional, Ead, Wahib S., additional, To, Iris, additional, Batlevi, Connie Lee, additional, Wei, Michael C., additional, and Chavez, Julio C., additional

Published
2023
Full Text
View/download PDF

41. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Author

Wang, Michael, primary, Jurczak, Wojciech, additional, Trněný, Marek, additional, Belada, David, additional, Wrobel, Tomasz, additional, Ghosh, Nilanjan, additional, Keating, Mary-Margaret, additional, van Meerten, Tom, additional, Fernandez Alvarez, Ruben, additional, von Keudell, Gottfried, additional, Thieblemont, Catherine, additional, Peyrade, Frederic, additional, Andre, Marc, additional, Hoffmann, Marc, additional, Szafer Glusman, Edith, additional, Lin, Jennifer, additional, Dean, James P., additional, Neuenburg, Jutta K., additional, and Tam, Constantine S., additional

Published
2023
Full Text
View/download PDF

42. Wide Composite Resection of Sternal Metastasis & Reconstruction Using Titanium Mesh Implant and Myocutaneous Flap in Differentiated Thyroid Carcinoma: Case Report of Two Cases

Author

Rojesara, Mit, primary, Sattavan, Swati, additional, Sharma, Mohit, additional, Rathod, Priyank, additional, Puj, Ketul, additional, Pandya, Shashank, additional, Bande, Vivek, additional, Pawar, Ajinkya, additional, Ghosh, Nilanjan, additional, Bhat S, Sankhya, additional, and Kumar M, Senthil, additional

Published
2023
Full Text
View/download PDF

43. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.

Author

Wang, Michael, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew, Hirayama, Alexandre V., Abramson, Jeremy S., Arnason, Jon, Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Dehner, Christine, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, Eliason, Laurie, and Palomba, M. Lia

Published
2024
Full Text
View/download PDF

44. Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia

Author

Hamadeh, Issam S., primary, Patel, Jai N., additional, Jacobs, Ryan, additional, Zeng, Hang, additional, He, Jiaxian, additional, Hu, Bei, additional, Moyo, Tamara Kay, additional, Soni, Amy, additional, Park, Steven, additional, Copelan, Ed, additional, Avalos, Belinda, additional, Hamilton, Alicia, additional, Steuerwald, Nury, additional, and Ghosh, Nilanjan, additional

Published
2023
Full Text
View/download PDF

47. MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

Author

Palomba, M. Lia, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V., additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Dehner, Christine, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results